NCT05669339 2026-02-18
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
Clinical Trials
6 trialsNCT01485744 2020-08-04
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01431794 2020-01-22
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT01911416 2016-06-09
A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
University of Utah
Phase NA Withdrawn
NCT01694589 2014-12-12
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Withdrawn